Silvia Comis News Today

NANTES, France, October 16, 2023--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, MA (October 11 – 15, 2023 - Abstract number 35371, Poster C063).

Tedopi is the Company's Most Advanced Product in Clinical Development ATALANTE-1, a Phase 3 clinical trial with positive results comparing Tedopi to chemotherapy in non-small cell lung cancer

In Addition, Three Senior Executives Will Reinforce the Company’s Drug Development Engine ...